These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
338 related articles for article (PubMed ID: 27913499)
21. The evolving role of targeted drugs in the treatment of Hodgkin lymphoma. Eichenauer DA; Engert A Expert Rev Hematol; 2017 Sep; 10(9):775-782. PubMed ID: 28665214 [TBL] [Abstract][Full Text] [Related]
22. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Younes A; Santoro A; Shipp M; Zinzani PL; Timmerman JM; Ansell S; Armand P; Fanale M; Ratanatharathorn V; Kuruvilla J; Cohen JB; Collins G; Savage KJ; Trneny M; Kato K; Farsaci B; Parker SM; Rodig S; Roemer MG; Ligon AH; Engert A Lancet Oncol; 2016 Sep; 17(9):1283-94. PubMed ID: 27451390 [TBL] [Abstract][Full Text] [Related]
23. Current and emerging treatment options for a patient with a second relapse of Hodgkin's lymphoma. Kallam A; Armitage JO Expert Rev Hematol; 2018 Apr; 11(4):293-300. PubMed ID: 29521140 [TBL] [Abstract][Full Text] [Related]
24. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use. Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039 [TBL] [Abstract][Full Text] [Related]
25. FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma. Kasamon YL; de Claro RA; Wang Y; Shen YL; Farrell AT; Pazdur R Oncologist; 2017 May; 22(5):585-591. PubMed ID: 28438889 [TBL] [Abstract][Full Text] [Related]
26. [Durable remission attained by long-term brentuximab vedotin administration in a relapsed post-allogeneic bone marrow transplant Hodgkin lymphoma patient]. Ono Y; Hiramoto N; Yoshioka S; Yabushita T; Koba Y; Tabata S; Imai Y; Ishikawa T Rinsho Ketsueki; 2017; 58(12):2397-2401. PubMed ID: 29332873 [TBL] [Abstract][Full Text] [Related]
27. Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma. Garciaz S; Coso D; Peyrade F; Fürst S; Duran S; Chetaille B; Brenot-Rossi I; Devillier R; Granata A; Blaise D; Bouabdallah R Hematol Oncol; 2014 Dec; 32(4):187-91. PubMed ID: 24301099 [TBL] [Abstract][Full Text] [Related]
29. Treating Hodgkin lymphoma in the new millennium: Relapsed and refractory disease. LaCasce AS Hematol Oncol; 2019 Jun; 37 Suppl 1():87-91. PubMed ID: 31187532 [TBL] [Abstract][Full Text] [Related]
30. Immunotherapy for Hodgkin lymphoma: From monoclonal antibodies to chimeric antigen receptor T-cell therapy. Maaroufi M Crit Rev Oncol Hematol; 2023 Feb; 182():103923. PubMed ID: 36702422 [TBL] [Abstract][Full Text] [Related]
31. Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors. Carella AM; Corradini P; Mussetti A; Ricardi U; Vitolo U; Viviani S Ann Hematol; 2018 Aug; 97(8):1301-1315. PubMed ID: 29802458 [TBL] [Abstract][Full Text] [Related]